The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.
The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics \u2013 as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.
Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.
Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease \u2013 the first inoculation to do so.
Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford\u2019s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.
Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Most NDDs are thought to be genetic and caused by changes to DNA, however, to date, around 60% of individuals with these conditions do not know the specific DNA change that causes their disorder.
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
New research published by scientists at the University of Oxford, the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa, and the Ragon Institute of Mass General, MIT and Harvard, USA, shows that male infants are more likely to achieve HIV cure/remission than females.
Great Ormond Street Hospital (GOSH) Charity has joined forces with Cancer Research UK (CRUK) to co-fund two projects that will use data science to advance research into childhood cancers.
New research, published today, has defined the functional impacts of hundreds of variants in a gene that is a major cause of neurodevelopmental disorders.
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
The Neuroimaging Group, at the Department of Paediatrics, in collaboration with Bliss, the charity for babies born premature or sick, has launched a new suite of information resources for parents of neo-nates, designed to make them feel more confident about being involved in the care of their babies.
Many congratulations to Associate Professor Carlo Rinaldi and Senior Postdoctoral Scientist Antonio Garcia-Guerra, who have been awarded the Novartis Global Scholar Program (NGSP) for 2023.
![\"\"](\"https://www.paediatrics.ox.ac.uk/news/spotlight-on-magdalen-college-chapel-for-rare-disease-day/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n